Similar to early clinical studies, our studies using Flt3L-DCs have demonstrated that the cancer vaccination of autologous DCs results in limited effects on a pre-established tumor [9, 12, 22–24] (Supplementary Fig. S1a, b). Here, FLT3LG is linked to cancer.